3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone;3-[3-(4-Methoxyphenyl)-1-oxo-2-propenyl]-4-phenyl-2(1H)-quinolinone;2(1H)-Quinolinone, 3-[3-(4-methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-;Ceranib-2 >=98% (HPLC);Ceranib-2, 10 mM in DMSO;3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]-4-phenyl-1,2-dihydroquinolin-2-one
Ceranib-2 is a potent non-lipid ceramidase inhibitor with anticancer activity; it inhibits ceramidase activity in SKOV3 cells (IC50 = 28 μM), induces accumulation of multiple ceramide species, reduces sphingosine and sphingosine-1-phosphate (S1P) levels, and triggers apoptosis; it suppresses cell proliferation and/or survival in vitro (IC50 = 0.73 μM in SKOV3 cells); it induces cell cycle arrest in sub-G1, G2, and S phases and decreases the proportion of cells in G1 phase; in vivo, it delays tumor growth in a syngeneic tumor model in female Balb/c mice without causing hematologic suppression or overt toxicity.